First Patient Enrolled in LYNX-2 Phase 3 Study Evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the Treatment of Decreased Visual Acuity Under Low Light Conditions Following Keratorefractive Surgery

April 11, 2024

https://www.globenewswire.com/news-release/2024/04/11/2861621/0/en/First-Patient-Enrolled-in-LYNX-2-Phase-3-Study-Evaluating-Phentolamine-Ophthalmic-Solution-0-75-PS-for-the-Treatment-of-Decreased-Visual-Acuity-Under-Low-Light-Conditions-Following.html

LYNX-2 Follows SPA Agreement with FDA

Development of PS is Funded by Ocuphire’s Partner Viatris

FARMINGTON HILLS, Mich., April 11, 2024 (GLOBE NEWSWIRE) — Ocuphire Pharma, Inc. (Nasdaq:OCUP), a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of unmet needs of patients with retinal and refractive eye disorders, today announced the enrollment of the first subject in the LYNX-2 Phase 3 registration study evaluating Phentolamine Ophthalmic Solution 0.75% (PS) for the treatment of decreased visual acuity under low (mesopic) light conditions following keratorefractive surgery.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.